Delcath Systems Inc. (NASDAQ: DCTH) announced that new data on its percutaneous hepatic perfusion with melphalan treatment was presented at the ESMO Breast Cancer Congress 2026 on May 7.

The presentation focused on a retrospective analysis conducted by independent investigators at three European centers examining the CHEMOSAT Hepatic Delivery System for treating liver-dominant metastatic breast cancer. The study evaluated 15 patients treated between September 2015 and May 2024.

According to the analysis, patients had received a median of four prior systemic therapy lines before treatment. The study found that 60% of patients achieved hepatic partial response, while 67% required blood transfusions. Grade 3-4 post-procedure adverse events occurred in 80% of patients, primarily bone marrow suppression with neutropenic-related infections.

The median overall survival from first treatment was 6.0 months, with 33% of patients alive at last follow-up. The median follow-up period was 55.6 months.

Gerard Michel, chief executive officer of Delcath Systems, stated the data represents real-world evidence supporting the use of their products in liver-dominant metastatic breast cancer patients.

The company's HEPZATO KIT is currently being evaluated in a randomized Phase 2 trial for metastatic breast cancer patients with liver dominant disease. The treatment is approved in the United States for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver.

The information was disclosed in a company press release.